Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Free Cash Flow: 2012-2024

Historic Free Cash Flow for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$20.4 million.

  • Coherus Oncology's Free Cash Flow rose 25.28% to -$46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.5 million, marking a year-over-year increase of 134.31%. This contributed to the annual value of -$20.4 million for FY2024, which is 88.33% up from last year.
  • As of FY2024, Coherus Oncology's Free Cash Flow stood at -$20.4 million, which was up 88.33% from -$175.2 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's Free Cash Flow peaked at $146.9 million during FY2020, and registered a low of -$243.2 million during FY2022.
  • Over the past 3 years, Coherus Oncology's median Free Cash Flow value was -$175.2 million (recorded in 2023), while the average stood at -$146.3 million.
  • As far as peak fluctuations go, Coherus Oncology's Free Cash Flow spiked by 453.70% in 2020, and later crashed by 527.99% in 2022.
  • Coherus Oncology's Free Cash Flow (Yearly) stood at $146.9 million in 2020, then plummeted by 126.36% to -$38.7 million in 2021, then slumped by 527.99% to -$243.2 million in 2022, then climbed by 27.96% to -$175.2 million in 2023, then skyrocketed by 88.33% to -$20.4 million in 2024.